#biotech-acquisition

#biotech-acquisition

Anthropic has purchased the stealth biotech AI startup Coefficient Bio in a $400 million stock deal, confirming its commitment to advancing healthcare and life sciences.

You just have to immerse yourself in it. You should just constantly be building. That's what's going to give you the best chance of having the relevant skill set that is needed to make a difference in technology.

Google's new health tracker, teased by Steph Curry, features a Whoop-inspired design and will include a subscription service with an AI-based personal health coach.

Incyte tops this list due to its rare combination of commercial scale, cash generation, and pipeline depth. The company posted FY2025 revenue of $5.14 billion, up 21.2% YoY, anchored by Jakafi generating $828.2 million in Q4 2025 alone (+7% YoY) and Opzelura delivering $207.3 million (+28% YoY). With $3.58 billion in cash and 14 pivotal clinical trials underway, Incyte offers an acquirer immediate revenue, margin expansion potential, and a deep oncology pipeline spanning KRASG12D, CDK2 inhibition, and mutCALR.

Four terabytes of data have reportedly been stolen, including database records and source code. Allegedly stolen data has been published on a leak site, containing Slack information, internal ticketing data, and videos of conversations between Mercor's AI systems and contractors.

Reports suggest that Stripe is considering a PayPal acquisition, although negotiations on the subject are in early stages with no guarantee of going through.

Nicolas Sauvage, president of TDK Ventures, will explain the unique operations of corporate VCs and what founders should know about attracting investment.

But he'd been considering an idea for new technology-an autonomous, wind-powered cargo ship. Then, while on paternity leave in 2024, he discovered a free program that helps scientists and engineers launch businesses for the first time. Weeks after finishing the program, called 5050, Cymbalist had launched a startup called Clippership. The company's first ship is being built in the Netherlands this year. Without the accelerator, he says, the company likely wouldn't exist.

We provide thought partnership. When a company is developing a drug, there's a lot of work involved, such as understanding the science, designing a study and generating good data. We come in and explain what the standard of care looks like today for their patient population, and what we think it will look like in five to eight years or whenever they plan to launch their therapy.